Oxford Biomedica

Oxford Biomedica (OXB) is a pioneering contract development and manufacturing organisation (CDMO) specialising in viral vector production for cell and gene therapies. With over 25 years of expertise, OXB provides comprehensive services from early-stage development to commercial manufacturing, enabling innovative therapies for patients worldwide.

OXB focuses on viral vector technologies, particularly in lentivirus, AAV, and adenovirus platforms. The company offers end-to-end capabilities, including plasmid design, development, and GMP manufacturing, supported by advanced analytics and regulatory expertise. OXB serves top pharmaceutical and biotech companies, helping to bring life-changing therapies to market.

Key Products and Services

• LentiVector® platform for lentiviral vectors
• inAAVate™ platform for AAV vector development
• Adenovirus and other viral vector services
• Process development, quality assurance, and regulatory support
• Full GMP manufacturing services for clinical and commercial products

OXB's dedication to innovation and quality ensures its leadership in the viral vector space, supporting the advancement of gene therapies that promise transformative patient outcomes.